Business Wire

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the DynamX ...
Business Insider

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...
Yahoo Finance

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...
Business Wire

Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized ...
CRM Buyer

Social Dynamx Turns CSRs Into Rock Stars

Social Dynamx has just launched a new enterprise-class social customer care (social CRM) platform that will allow customer support and community management teams to identify, prioritize and handle ...
EDN

Social Dynamx Launches to Redefine Social Customer Care

Consumers now broadcast their opinions instantly to thousands, or even millions, of people from wherever they are. Social Dynamx quickly identifies relevant conversations and intelligently routes them ...
EurekAlert!

DynamX Bioadaptor, a novel 'uncaging' platform for coronary artery revascularisation

Drug Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% ...
VentureBeat

Update: Lithium Technologies issues $5.6M in shares to buy Social Dynamx

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Lithium Technologies has issued $5.6 million in shares to power its ...
TechCrunch

Lithium Acquires Social CRM Application For Call Centers, Social Dynamx

Social CRM company Lithium Technologies has acquired fellow customer care application Social Dynamx. The financial terms of the deal were not disclosed. Social Dynamx’s platform is designed for large ...
Yahoo Finance

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

MILPITAS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced new landmark clinical results for its ...
manilatimes

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...